Finance

Lists
600998:SHA
Jointown Pharmaceutical Group Co Ltd
CN¥5.22
+1.36%
(+0.070) 1D
Oct 30, 3:00:00 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600998...
Open
CN¥5.15
High
CN¥5.27
Low
CN¥5.10
Mkt. cap
26.32B
Avg. vol.
37.82M
Volume
57.54M
Dividend
3.83%
Quarterly dividend
CN¥0.05
Ex-dividend date
Jun 8, 2026
P/E ratio
13.42
52-wk high
CN¥5.84
52-wk low
CN¥4.48
EPS
CN¥0.39
Shares outstanding
1.88B
No. of employees
30K
Open
CN¥5.15
High
CN¥5.27
Low
CN¥5.10
Mkt. cap
26.32B
Avg. vol.
37.82M
Volume
57.54M
Dividend
3.83%
Quarterly dividend
CN¥0.05
Ex-dividend date
Jun 8, 2026
P/E ratio
13.42
52-wk high
CN¥5.84
52-wk low
CN¥4.48
EPS
CN¥0.39
Shares outstanding
1.88B
No. of employees
30K
News stories
From web sources and news partners
Profile
Jointown Pharmaceutical Group Co., Ltd. is a publicly traded multinational healthcare services company. By revenue, it is the largest medical company in China that is not state-owned. It is also the 4th largest overall. Its global headquarters are in Wuhan, China and its international headquarters are in Los Angeles, California. The company specializes in the distribution of pharmaceuticals and medical products, distributing more than 510,000 products. The company also manufactures products, including gloves, surgical masks, medical equipment and medications. In addition, it operates the largest network of medical warehouses in China. It is one of the largest in the world, at over 44 million square feet. The company has over 400 subsidiaries and provides medical products to all 31 provinces in mainland China. Wikipedia
About Jointown Pharmaceutical Group Co Ltd
CEO-
Employees29.9K
Founded2000
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
42.06B
44.78B
42.50B
42.17B
Cost of goods sold
38.94B
41.44B
39.12B
38.44B
Cost of revenue
38.94B
41.44B
39.12B
38.44B
Research and development expenses
31.05M
24.25M
35.77M
39.59M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.21B
2.07B
2.24B
2.43B
Operating expense
2.54B
2.37B
2.45B
2.54B
Total operating expenses
41.49B
43.81B
41.57B
40.99B
Operating income
577.21M
971.28M
922.06M
1.18B
Other non operating income
-23.03M
-15.38M
-57.14M
4.31M
EBT including unusual items
590.98M
762.47M
810.81M
724.15M
EBT excluding unusual items
402.66M
702.61M
619.67M
952.94M
Income tax expense
258.61M
167.28M
213.41M
156.22M
Effective tax rate
43.76%
21.94%
26.32%
21.57%
Other operating expenses
209.56M
45.26M
169.00M
-10.17M
Net income
279.41M
733.16M
467.41M
481.61M
Net profit margin
0.66%
1.64%
1.10%
1.14%
Earnings per share
0.05
0.11
0.08
0.12
Interest and investment income
122.28M
65.73M
31.49M
27.77M
Interest expense
-262.58M
-319.03M
-279.26M
-256.55M
Net interest expenses
-140.30M
-253.30M
-247.77M
-228.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
728.70M
1.12B
1.11B
1.33B
Gain or loss from assets sale
244.27M
-
20.61M
-20.61M
Upcoming events
AI content may include mistakes. Learn more
Google apps